Companies › SUNHO(China)BioPharmaceutical
4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IAH0968 HER2-targeting biologic (mechanism unclear from registry) | – | Phase 2 | Stomach Neoplasms | Jul 2028 |
| IAP0971 PD-L1 inhibitor | – | Phase 1 | Advanced Malignant Tumors; Advanced Malignant Neoplasm | Mar 2027 |
| IBD0333 | – | Phase 1 | MTD | Dec 2029 |
| IBB0979 unclear - immunotherapy agent | – | Phase 1 | Advanced Malignant Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05991583 | IBB0979 | Phase 1 | Advanced Malignant Tumors | Oncology | Nov 2025 |
| NCT06223841 | IAP0971 | Phase 1 | Advanced Malignant Tumors | Oncology | Mar 2027 |
| NCT06504732 | IAH0968 | Phase 2 | Stomach Neoplasms | Oncology | Jul 2028 |
| NCT06581419 | IAP0971 | Phase 1 | Advanced Malignant Neoplasm | Oncology | Aug 2029 |
| NCT06292208 | IBD0333 | Phase 1 | MTD | Other | Dec 2029 |
No annotated target.
–
GI Innovation OBI Pharma Ranok Therapeutics (Hangzhou) Shanghai EpimAb Biotherapeutics Tyra Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.